하이드록시클로로퀸 시장 : 적응 질환별, 유통 채널별, 지역별

Hydroxychloroquine Market is estimated to be valued at USD 670.3 Mn in 2025 and is expected to reach USD 988.1 Mn by 2032, growing at a compound annual growth rate (CAGR) of 5.7% from 2025 to 2032.

Hydroxychlorquine exhibits the potential invitro activity against viruses including influenza, malaria, coronavirus, and many other diseases. The drug is under investigation to determine its efficacy for the treatment of novel coronavirus disease (COVID 19). According to the studies conducted in Wuhan, the body temperature recovery time and the cough remission time of coronavirus patients were significantly reduced with hydroxycloroquine and chloroquine treatment.Despite the absence of strong evidence, the demand for hydroxychloroquine has spiked due to the coronavirus (COVID 19) outbreak. However, the doses of hydroxychloroquine need to be monitored, as its overdose can have dangerous side effects such as drowsiness, visual disturbances, cardiovascular collapse, convulsions, hypokalemia, rhythm, ventricular tachycardia, and ventricular fibrillation. This may lead to sudden respiratory and cardiac arrest, which can be fatal.

Market Dynamics

The increasing adoption of inorganic growth strategies such as partnerships and collaborations by key players to evaluate the efficacy of hydroxchloroquine tablets for the treatment of patients with coronavirus disease (COVID 19) are expected to propel the market growth over the forecast period. For instance, on March 27, 2020, Rising Pharma Holdings Inc., a pharmaceutical company, entered into a collaborative agreement with the Division of Infectious Disease and International Medicine at the University of Minnesota, Department of Infectious Disease, to explore hydroxchloroquine as preventive treatment for coronavirus disease (COVID 19).

Key features of the study:

• This report provides in-depth analysis of the global hydroxchloroquine market, and provides market size (US$ Mn) and compound annual growth rate (CAGR) for the forecast period 2025-2032, considering 2024 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global hydroxchloroquine market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans.
• Key companies covered as a part of this study include Sanofi, Amneal Pharmaceuticals, LLC, Laurus Labs, Zydus Group, Prasco, LLC, Dr. Reddy's Laboratories, Ltd, Cadila Pharmaceuticals, Novartis AG, Concordia Pharmaceuticals Inc. (A subsidiary of Advanz Pharma), Covis Pharma GmbH, Cardinal Health, Aphena Pharma Solutions, Mylan N.V (A subsidiary of Vitris), McKesson Corporation, Teva Pharmaceutical Industries Ltd, Lupin, Sun Pharmaceutical Industries Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future drug launches, disease indication up-gradation, market expansion, and marketing tactics.
• The global hydroxchloroquine market report caters to various stakeholders in this industry including investors, suppliers, drug manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hydroxchloroquine market.

Detailed Segmentation:

• Global Hydroxychloroquine Market, By Disease Indication:
  • Malaria
  • Coronavirus
  • Lupus Erythematosus
  • Rhematoid Arthritis
• Global Hydroxychloroquine Market, Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Hydroxychloroquine Market, By Region:
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • Central Africa
  • North Africa
• Company Profiles
  • Sanofi
  • Amneal Pharmaceuticals, LLC,
  • Laurus Labs,
  • Zydus Group
  • Prasco, LLC
  • Reddy's Laboratories, Ltd
  • Cadila Pharmaceuticals
  • Novartis AG,
  • Concordia Pharmaceuticals Inc. (A subsidiary of Advanz Pharma)
  • Covis Pharma GmbH
  • Cardinal Health
  • Aphena Pharma Solutions,
  • Mylan N.V (A susidary of Vitris)
  • McKesson Corporation
  • Teva Pharmaceutical Industries Ltd
  • Lupin, Sun Pharmaceutical Industries Ltd

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Disease Indication
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Country
    • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Regulatory Scenario
• Industry Trends
• New Disease Indication Approval/Launches
• Promotion And Marketing Initiatives
• Impact Analysis
• Recent Product Launches
• Epidemiology
• Merger, Acquisition, and Collaborations
• Regulatory Scenario
• Key Developments
• PEST Analysis

4. Global Hydroxychloroquine Market- COVID-19 Impact Analysis

• Economic Impact
• COVID-19 Epidemiology
• Impact on Supply and Demand

5. Global Hydroxychloroquine Market, By Disease Indication, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021-2032
  • Segment Trends
• Malaria
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Mn)
• Coronavirus Disease
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Mn)
• Lupus Erythematosus
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Mn)
• Rheumatid Arthritis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Mn)

6. Global Hydroxychloroquine Market, By Distribution Channel, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021-2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Mn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Mn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Mn)

7. Global Hydroxychloroquine Market, By Region, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Regions, 2021-2032
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020 - 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel 2020 - 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Mn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020 - 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, Distribution Channel, 2020 - 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020 - 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, Distribution Channel, 2020 - 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020- 2032, (US$ Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020 - 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, Distribution Channel, 2020 - 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020- 2032, (US$ Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020 - 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, Distribution Channel, 2020 - 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020- 2032, (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020 - 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, Distribution Channel, 2020 - 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020- 2032, (US$ Mn)
    • North Africa
    • Central Africa
    • South Africa

8. Competitive Landscape

• Sanofi
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Amneal Pharmaceuticals, LLC
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Laurus Labs
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Zydus Group
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Prasco, LLC
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Reddy's Laboratories, Ltd
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Cadila Pharmaceuticals
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Novartis AG
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Concordia Pharmaceuticals Inc. (A subsidiary of Advanz Pharma)
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Covis Pharma GmbH
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Cardinal Health
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Aphena Pharma Solutions
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Mylan N.V (A subsidiary of Viatris)
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• McKesson Corporation
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Teva Pharmaceutical Industries Ltd
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Lupin
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Sun Pharmaceutial Industries Ltd
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies

9. Section

• Research Methodology
• About Us